Allena Pharmaceuticals, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ALNA research report →
Companywww.allenapharma.com
Allena Pharmaceuticals, Inc. , a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease.
- CEO
- Louis Brenner
- IPO
- 2017
- Employees
- 12
- HQ
- Newton, MA, US
Price Chart
Valuation
- Market Cap
- $0
- P/E
- -0.07
- P/S
- 0.00
- P/B
- 0.13
- EV/EBITDA
- 0.92
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -160.99%
- ROIC
- -166.72%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-33,355,000 · -1.55%
- EPS
- $-1.03 · -1.98%
- Op Income
- $-32,335,000
- FCF YoY
- -60.87%
Performance & Tape
- Beta
- 1.15
Get TickerSpark's AI analysis on ALNA
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Feb 1, 22 | Katz Richard D | other | 255,000 |
| Feb 1, 22 | BRENNER LOUIS MD | other | 655,000 |
| Nov 15, 21 | BRENNER LOUIS MD | other | 125,582 |
| Nov 15, 21 | BRENNER LOUIS MD | sell | 40,328 |
| Nov 15, 21 | BRENNER LOUIS MD | other | 125,582 |
| Jun 3, 21 | Margolin Alexey L | other | 37,000 |
| Jun 3, 21 | Alexander Robert | other | 37,000 |
| Jun 3, 21 | Diaz Allene M. | other | 37,000 |
| Jun 3, 21 | SANTINI GINO | other | 37,000 |
| Jun 3, 21 | Miller Ann Calby | other | 37,000 |
Our ALNA Coverage
We haven't published any research on ALNA yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate ALNA Report →